The sale is a win for Bristol-Myers Squibb, which is working to overcome antitrust concerns to secure approval for its $74 billion acquisition of Celgene.
Bristol-Myers said in June it would sell Otezla to ease concerns raised by the Federal Trade Commission because of a competing treatment it is developing.
Otezla had $1.61 billion in sales last year. Amgen expects sales from the drug to increase over the next five years.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
